Nicox Announces Shareholder Q&A Webpage Available

Core Points - Nicox SA has launched a new "Q&A" webpage on its website to address frequently asked questions from shareholders [1] - The company is focused on developing innovative ophthalmology solutions to maintain vision and improve ocular health [2] Company Overview - Nicox SA is an international ophthalmology company headquartered in Sophia Antipolis, France, and is listed on Euronext Growth Paris under the ticker symbol ALCOX [3] - The company's lead clinical program is NCX 470, a nitric oxide-donating bimatoprost eye drop aimed at lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension [2] - Nicox has licensed NCX 470 to Ocumension Therapeutics for the Chinese, Korean, and Southeast Asian markets, and to Kowa for the rest of the world [2] - The company also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, in collaboration with Glaukos [2] - Nicox's first product, VYZULTA®, is commercially available in the U.S. and over 15 other territories, licensed exclusively worldwide to Bausch + Lomb [2] - The company generates revenue from ZERVIATE® for allergic conjunctivitis, licensed in multiple geographies [2]